Madrid

• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended recruitment
  2023-506368-14-00 5 2021-09-07 Systemic lupus erythematosus (SLE)
• A Phase 2 Study of Avutometinib (VS-6766) Alone and In Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAM … Ended recruitment
  2024-516986-35-00 4 2021-09-06 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
• Long term access to berotralstat for HAE subjects from previous clinical trials. Ended recruitment
  2024-511285-37-00 11 2021-08-31 Hereditary Angioedema
• A Study of the Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis Ended recruitment
  2023-504734-21-00 5 2021-08-30 Psoriatic arthritis (PsA)
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tu … Ended recruitment
  2023-508194-89-00 4 2021-08-30 Persistent or Recurrent Rare Epithelial Ovarian Tumors
• Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors Ended recruitment
  2023-503905-12-00 4 2021-08-20 Liver cancer; Colon cancer; Pancreatic cancer; Bile Duct or Gallbladde
• A Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With MM Who Are Refractory to at Least One PI, One IMiD and One Ant … Ended recruitment
  2023-504479-25-00 4 2021-08-20 Multiple myeloma
• Trastuzumab Deruxtecan for Subjects with HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma after Progression on or A … Ended recruitment
  2023-507963-20-00 5 2021-08-19 Metastatic Gastric Adenocarcinoma
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len … Ended recruitment
  2023-505850-16-00 5 2021-08-05 Multiple Myeloma
• Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic … Ended recruitment
  2023-506752-24-00 5 2021-08-05 Locally recurrent inoperable or metastatic HR+/HER2- breast cancer, wh
• PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll … Ended recruitment
  2024-511321-54-00 5 2021-08-04 intermediate-high-risk acute pulmonary embolism
• Study of Subcutaneous Pembrolizumab versus Intravenous Pembrolizumab, Given with Chemotherapy, to Treat Metastatic Squamous or Non Squamous … Ended recruitment
  2023-508308-40-00 5 2021-07-30 Metastatic (stage IV) squamous or nonsquamous non-small cell lung canc
• Study of AZD5305 as Monotherapy and with Anti-Cancer Agents in Patients with Advanced Solid Malignancies Ended recruitment
  2022-502856-29-00 7 2021-07-27 Advanced Solid Tumors
• DALY 2-EU Ended recruitment
  2023-506270-13-00 4 2021-07-27 Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)
• Phase 2 Study of Axatilimab at 3 Different Doses in Patients with Chronic Graft Versus Host Disease. Ended recruitment
  2024-512978-99-00 4 2021-07-19 Chronic graft versus host disease (cGVHD)
• "Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)" Ended recruitment
  2024-516754-22-00 4 2021-07-14 Pulmonary Arterial Hypertension (PAH)
• Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With Nusinersen … Ended recruitment
  2023-505637-27-00 5 2021-07-12 Spinal Muscular Atrophy
• A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Ended recruitment
  2023-506585-31-00 1 2021-07-09 Metastatic castration-resistant prostate cancer
• A Phase 3 Open Label, Randomized Study of LOXO 305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab … Ended recruitment
  2023-507697-40-00 5 2021-07-05 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A Study Evaluating the Efficacy and Safety of Crovalimab in Adult and Adolescent Patients with atypical Hemolytic Uremic Syndrome (aHUS) Ended recruitment
  2023-505089-27-00 5 2021-07-01 Atypical Hemolytic Uremic Syndrome (aHUS)
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination with other Anti-Cancer Therap … Ended recruitment
  2023-506311-18-00 1 2021-06-29 Advanced or metastatic solid tumors with KRAS G12C mutation
• A Multi Arm Study in Participants with MSI-High Metastatic Colorectal Cancer Ended recruitment
  2022-502100-70-00 10 2021-06-23 Participants with Microsatellite Instability-High (MSI-H) or Mismatch
• Efficacy and Safety Comparison of Niraparib to Placebo in Participants with HER2 Negative BRCAmut or Triple-Negative Breast Cancer with Mole … Ended recruitment
  2023-504454-35-00 5 2021-06-22 Neoplasms, Breast
• Phase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer (ABACUS-2) Ended recruitment
  2024-510750-28-00 4 2021-06-18 Tumours of the urothelial tract requiring surgery (T1 high grade-T4a o

Showing 2,281–2,304 of 3,550 trials